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PCLINICAL RESEARCH Antiplatelet Therapy
Long-Term Clinical Outcome Based on
Aspirin and Clopidogrel Responsiveness Status
After Elective Percutaneous Coronary Intervention
A 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing
Resistance to Aspirin and/or Resistance to Clopidogrel) Trial Substudy
Gianluca Campo, MD,*† Luca Fileti, MD,*† Nicoletta de Cesare, MD,‡ Emanuele Meliga, MD,§
Alessandro Furgieri, MD, Filippo Russo, MD,¶ Salvatore Colangelo, MD,# Salvatore Brugaletta, MD,**
Roberto Ferrari, MD, PHD,*† Marco Valgimigli, MD, PHD,*† on behalf of the 3T/2R Investigators
Ferrara, Lumezzane, Zingonia, Turin, Cotignola, and Pavia, Italy; and Barcelona, Spain
Objectives The purpose of this study was to investigate the long-term outcome after elective percutaneous coronary inter-
vention in low-risk patients screened for aspirin and/or clopidogrel responsiveness in the 3T/2R (Tailoring Treat-
ment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial.
Background The impact of aspirin and/or clopidogrel poor response on long-term outcome is debated.
Methods Aspirin and clopidogrel response was measured with the VerifyNow system aspirin and P2Y12 assays. After per-
cutaneous coronary intervention (PCI), death, stroke, and myocardial infarction were assessed up to 1 year.
Results Overall, 1,277 patients were screened, and 826 (65%) were treated with PCI. In all, 124 patients were found to
be aspirin poor responders, and there were 179 clopidogrel poor responders (totally, 278 poor responders). The
1-year end point was significantly higher in poor responders as compared to full responders (15.8% vs. 8.6%,
p  0.002), which is principally due to more myocardial infarction occurrence. At multivariable analysis, clopi-
dogrel poor response emerged as an independent predictor (hazard ratio: 1.15, 95% confidence interval: 1.03 to
1.28). Receiver-operator characteristic analysis identifies 23 of percentage of platelet inhibition and 208 of P2Y12
reactivity units as optimal cut offs to predict 1-year end point. Excluding periprocedural events, also peri-PCI myocar-
dial infarction, which is strongly related to aspirin/clopidogrel poor response, was an independent predictor (hazard
ratio: 1.25, 95% confidence interval: 1.14 to 1.37). Glycoprotein IIb/IIIa inhibitor administration reduces this risk in
poor responders (21.2% vs. 34.7%, p  0.02), but not in full responders (6.3% vs. 6.5%, p  0.8).
Conclusions Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse
1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse
outcome. Contrary to what was observed in poor responders, glycoprotein IIb/IIa inhibitor therapy failed to pro-
vide a benefit in aspirin and/or clopidogrel full responders. (J Am Coll Cardiol 2010;56:1447–55) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.103c
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Outcomes and Post-PCI Aspirin and Clopidogrel Responsiveness October 26, 2010:1447–55Previous studies largely focusing
on patients with intermediate-
to high-risk clinical features have
shown that poor responders to
aspirin and/or clopidogrel under-
going PCI are at greater risk for
death, myocardial infarction (MI),
and ST (4–6). Contrarily, the
prognostic implications of aspi-
rin and/or clopidogrel poor re-
sponsiveness in low-risk patients
undergoing elective PCI is still
elusive. Moreover, while light
transmittance aggregometry still
to date remains the gold stan-
dard, it is time consuming, tech-
nically demanding, and not avail-
able in most centers, limiting its
road-scale application in the clinical setting.
As part of a pre-specified substudy of the 3T/2R (Tailoring
reatment With Tirofiban in Patients Showing Resistance to
spirin and/or Resistance to Clopidogrel) trial (7), we sought
o investigate the long-term clinical outcomes of aspirin,
Figure 1 Study Profile
CABG  coronary artery bypass graft surgery; CK-MB  creatine kinase-myocardia
Abbreviations
and Acronyms
ARU  aspirin reactivity
unit
AUC  area under the
curve
COX  cyclooxygenase
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous
coronary intervention
%PI  percentage of
platelet inhibition
PRU  P2Y12 reactivity
unit
ST  stent thrombosislopidogrel, or dual poor responders undergoing elective
CI through a commercially available point of care.
ethods
atients. This is a pre-specified substudy of the 3T/2R
rial (7,8). Accordingly, inclusion and exclusion criteria have
een previously reported (7,8). Briefly, in the 3T/2R main
tudy, 263 low-risk patients (with stable coronary artery
isease and negative cardiac markers) undergoing PCI who
ere poor responders to aspirin and/or clopidogrel were
nrolled and randomly assigned to placebo or tirofiban. We
ound a significant reduction of the primary end point
periprocedural MI) and of adverse events at 30 days in the
rm receiving tirofiban. Contrarily, this study reports the
ong-term clinical outcome (1 year) of all patients screened
or aspirin and/or clopidogrel response (both full and poor
esponders) who are treated after coronary artery angiogra-
hy with PCI. Figure 1 illustrates the study profile and
utlines the different study groups.
creening procedure to evaluate aspirin and clopidogrel
oor/full response. A screening procedure to assess aspirin
esponsiveness was performed in patients at steady-state for
; PCI  percutaneous coronary intervention; pts  patients; ve  positive.l band
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October 26, 2010:1447–55 Outcomes and Post-PCI Aspirin and Clopidogrel Responsivenessspirin (80 mg/day for at least 5 days) (7,8). Clopidogrel
esponsiveness was measured in patients at steady-state for
oth aspirin and clopidogrel, the latter being defined as 600
g at least 2 h before or 300 mg at least 6 h before or 75
g/day for at least 7 days (7,8). Blood sample for screening
as always collected before coronary artery angiography and
CI procedures.
latelet function testing. To perform the screening pro-
edure, the VerifyNow system (Accumetrics, San Diego,
alifornia) was employed (7,8). Specific assays to test
spirin (VerifyNow Aspirin) and clopidogrel (VerifyNow
2Y12) are available. In the VerifyNow Aspirin assay, the
esult is expressed as aspirin reaction unit (ARU). The
erifyNow P2Y12 assay was used to evaluate the clopi-
ogrel effect on the P2Y12 receptor. The results are ex-
ressed in P2Y12 reaction units (PRU). The P2Y12 assay
ives also a baseline PRU value, and using PRU and
aseline PRU values determines the percentage of platelet
nhibition (%PI) by clopidogrel.
efinitions, study medications, and interventions. An
RU 550 identifies aspirin full responders, whereas an
aseline Characteristics of the Patients According to Aspirin and CTable 1 Baseline Characteristics of the Patients According to
Full Responders
Either
(n  548)
Both
(n  135)
Aspirin
(n  441)
Age, yrs 68 12 67 13 68 13
Male sex 418 (76) 102 (76) 331 (75)
Diabetes mellitus 123 (23) 31 (25) 111 (25)
OH treatment 97 (18) 24 (18) 84 (19)
Insulin treatment 27 (5) 9 (7) 27 (6)
Hypertension 399 (73) 98 (72) 320 (71)
Hyperlipidemia 323 (59) 84 (62) 262 (59)
Current cigarette use 164 (30) 48 (35) 128 (30)
Prior MI 202 (37) 48 (35) 150 (35)
Prior PCI 183 (33) 49 (36) 136 (31)
Prior CABG 50 (9) 15 (10) 35 (8)
LVEF, % 54 10 54 10 55 10
Clinical presentation
Silent ischemia 151 (27) 34 (25) 110 (24)
Stable angina 196 (36) 55 (40) 178 (40)
Low-risk UA 201 (37) 46 (35) 156 (36)
Angiographic features
Multivessel 341 (62) 88 (64) 282 (64)
Multivessel PCI 159 (30) 42 (31) 140 (32)
Number of stents 1.2 0.4 1.2 0.5 1.2 0.4
Drug-eluting stent 377 (68) 101 (75) 293 (66)
Medical therapy
GP IIb/IIIa inhibitors 116 (21) 27 (20) 98 (22)
Aspirin at 1 yr 537 (95) 130 (96) 431 (98)
Clopidogrel at 1 yr 444 (81) 108 (80) 353 (80)
ACE inhibitors 318 (58) 81 (60) 256 (58)
Beta-blockers 340 (62) 85 (63) 273 (62)
Statins 351 (64) 87 (65) 282 (64)
alues are mean  SD or n (%). *p  0.05 versus full responders to both. †p  0.05 versus full re
spirin.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft; GP  glycoprotein; L
CI  percutaneous coronary intervention; UA  unstable angina.RU 550 indicates aspirin poor responders (7,8). Full
esponse to clopidogrel is indicated by %PI 40%, whereas
PI 40% identifies poor responders (7,8). Of note, we
efined patients as “full or poor responder to both” if they
ere screened for both aspirin and clopidogrel response;
hereas the nonspecific term “full or poor responders” (or
he term full/poor responders to either) identified patients
valuated for aspirin and/or clopidogrel response (Table 1).
spirin (100 mg/day) was given to all patients indefinitely.
lopidogrel (75 mg/day) was given for at least 1 month to
atients with stable disease as an indication for PCI and
eceiving bare metal stent implantation, whereas it was
iven for at least 1 year to patients with unstable angina
nd/or who were receiving drug-eluting stent implantation.
n poor responders, which were included in the 3T/2R main
tudy, the use of tirofiban was randomized as previously
eported (7,8). Conversely, in other patients, the use and
ype of glycoprotein (GP) IIb/IIIa inhibitors were according
o the operator’s choice.
linical end points and follow-up. In the 3T/2R main
tudy, we reported the periprocedural MI occurrence (pri-
ogrel Responsein and Clopidogrel Response
Poor Responders
pidogrel
 289)
Either
(n  278)
Both
(n  25)
Aspirin
(n  124)
Clopidogrel
(n  179)
 11 68 10 74 14* 69 10 67 10
9 (76) 200 (72) 14 (56) 84 (68) 130 (73)
1 (21) 75 (27) 6 (24) 31 (25) 50 (28)
9 (17) 57 (20) 6 (24) 25 (20) 38 (21)
7 (6) 25 (9) 1 (4) 9 (7) 17 (9)
0 (72) 198 (71) 22 (88) 84 (68) 136 (76)
9 (58) 148 (53) 17 (68) 66 (56) 99 (55)
4 (32) 46 (16)† 5 (20) 25 (20) 26 (14)‡
1 (41) 117 (42) 4 (16) 46 (37) 75 (42)
6 (40) 107 (38) 6 (24) 34 (27) 79 (44)
2 (11) 19 (7) 0 (0) 7 (6) 12 (7)
 10 55 10 54 9 55 9 56 9
1 (31) 68 (24) 5 (20) 26 (21) 47 (26)
2 (32) 117 (42) 12 (48) 69 (56)‡ 60 (33)
6 (37) 93 (33) 8 (32) 29 (23)‡ 72 (40)
7 (61) 201 (78) 18 (72) 95 (77) 124 (69)
8 (27) 95 (34) 3 (12) 40 (32) 58 (32)
 0.4 1.2 0.4 1.2 0.3 1.2 0.5 1.3 0.5
9 (79) 183 (66) 20 (80) 70 (56) 133 (74)
6 (19) 146 (52)† 12 (48)* 68 (55)§ 90 (50)‡
4 (98) 269 (97) 24 (96) 119 (96) 174 (97)
3 (84) 233 (84) 22 (88) 102 (82) 153 (85)
8 (58) 161 (58) 15 (60) 72 (58) 104 (58)
9 (62) 202 (73) 16 (64) 78 (63) 140 (63)
5 (64) 181 (65) 16 (64) 81 (65) 116 (65)
rs to either. ‡p  0.05 versus full responders to clopidogrel. §p  0.05 versus full responders tolopidAspir
Clo
(n
67
21
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4
1
21
16
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3
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spondeVEF  left ventricular ejection fraction; MI  myocardial infarction; OH  oral hypoglycemic;
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Outcomes and Post-PCI Aspirin and Clopidogrel Responsiveness October 26, 2010:1447–55ary end point) and 30-day incidence of death, MI, and
rgent target vessel revascularization only in poor responder
atients who were randomly allocated to placebo or tirofiban
8). The current analysis reports the 1-year follow-up data
f all screened patients receiving PCI. Thus, the primary
bjective of this substudy was the 1-year occurrence of
eath, MI, and stroke. Myocardial infarction is defined as
n elevation of creatine kinase-myocardial band (CK-MB)
3 times the upper limit of normal (ULN). According to
he recent universal definition of MI and the 3T/2R main
tudy (8,9), periprocedural MI is also reported as elevation
f troponin I/T ratio 3 times ULN within 48 h after
ompletion of PCI. To better evaluate and describe peripro-
edural and late adverse events, we performed landmark
nalysis, with landmark set at 3 days. Finally, definite and
robable ST occurrence according to the Academic Re-
earch Consortium classification and bleedings according to
he criteria of the TIMI (Thrombolysis In Myocardial
nfarction) trial were assessed.
tatistical analysis. Continuous data are presented as
ean  SD. They were tested for normal distribution with
he Kolmogorov-Smirnov test and with the significance of
ifferences judged by t test. Categorical variables were
ummarized in terms of number and percentages and were
ompared using 2-sided Fisher exact test. Spearman’s cor-
elation coefficients were used to detect any association
etween variables. Survival curves were constructed by the
aplan-Meier method, and survival among groups was
ompared using the log-rank test. Cox proportional hazards
odels were used to assess risk reduction of adverse events.
ultivariable analysis, considering all clinical or angio-
raphic variables differently distributed (using a p value
0.20 as a threshold) and also GP IIb/IIIa inhibitor
herapy, was performed to identify independent predictors
or adverse events. Ability to discriminate between patients
ith and without adverse events was evaluated by receiver-
perating characteristic (ROC) curve analysis. The best
rognostic cut off for freedom from composite end point
as defined as the 1 that maximized both sensitivity and
pecificity. A 2-sided value of p  0.05 was considered
ignificant. All analyses were performed with STATIS-
ICA version 8 (StatSoft, Tulsa, Oklahoma) and STATA
ersion 9.2 (StataCorp LP, College Station, Texas).
esults
n all, 1,277 patients were screened for responsiveness to
spirin, clopidogrel or both, of whom 826 (64.7%) under-
ent PCI and represent our study population (Fig. 1). Of
he total group, 358 patients were screened for aspirin
esponsiveness only, of whom 96 (26.8%) were aspirin poor
esponders; of 261 patients who underwent assessment for
lopidogrel responsiveness only, 110 (42.1%) satisfied drug
oor responsiveness criteria, whereas 207 underwent screen-
ng for both oral antiplatelet agents. In the latter group, 44
21.9%) were only clopidogrel poor responders, 3 (1.5%) rere only aspirin poor responders, and 25 (12.1%) were
oor responders to both. Thus, the prevalence of aspirin
oor responsiveness among patients who underwent the
ual screening process was markedly lower (13.5%) than
mong patients, who, being at steady state for aspirin but
ot clopidogrel, were only screened for the former drug
26.8%, p  0.003). Hence, the final patient population
onsisted of 548 aspirin and/or clopidogrel full responders,
f whom 116 received GP IIb/IIIa inhibitors at the time of
CI per physician preference; 278 aspirin and/or clopi-
ogrel poor responders, of whom 132 received treatment
ith GP IIb/IIIa inhibitor at the time of PCI as per
andomization scheme; and 14 patients who failed to satisfy
ll inclusion/exclusion study criteria and were given GP
Ib/IIIa inhibitor per physician preference (Table 1).
aseline characteristics. Table 1 resumes baseline charac-
eristics of study population. The ARU values were not
ormally distributed, and we observed the first peak around
75 (responders) and a second peak around 570 (poor
esponders) (Fig. 2A). Contrarily, as already seen, %PI
mean 48.3, median 49, lower quartile 24.8, upper quar-
ile 68) and PRU (mean 142.1, median 139, lower quartile
6, upper quartile 196) values were both normally distrib-
ted and were highly correlated (r  86) (Fig. 2B). The
re-specified threshold of %PI40% corresponded to PRU
alue in the range of 165 in regression analysis (Fig. 2B).
linical outcomes. At 1 year, there were 18 (2.2%) deaths,
0 (9.7%) MIs, and 2 (0.2) strokes. The 1-year composite
nd point of overall mortality, MI, and stroke was higher for
spirin or clopidogrel poor responders (15.8%) as well as for
ual poor responders (20%), compared with responders
8.6%; p  0.002 and p  0.07, respectively), largely driven
y a higher rate of MI (Table 2). Definite ST was twice as
requent among poor responders (1.8%) as compared with
ull aspirin and/or clopidogrel responders (0.9%, p  0.2)
Table 2). At multivariable analysis, clopidogrel and not
spirin poor response emerged as an independent predictor
f worse outcomes (Table 3). A %PI 23% (AUC: 0.67,
5% CI: 0.52 to 0.81; sensitivity 66% and specificity 71%)
nd a PRU value 208 (AUC: 0.7, 95% CI: 0.58 to 0.8;
ensitivity 69% and specificity 76%) were identified as
ptimal cut offs to predict 1-year composite end point. At
ensitivity analysis focused on patients who did not receive
P IIb/IIIa inhibitors, the cut offs remained largely un-
hanged. In addition, no significant difference was observed
or the incidence of major and minor bleeding (Table 2).
andmarks analyses. 0 TO 3 DAYS. Within day 3, there
ere 55 (6.6%) MIs, of which 54 were index PCI-related,
nd 1 event occurred after staged PCI that was performed at
ay 2. Poor responders showed a significantly higher MI
ate (10.1% vs. 4.9%, p 0.008) (Table 2). Clopidogrel and
ot aspirin poor response emerged as an independent
redictor after adjustment for potential confounders (Table 3).
nterestingly, periprocedural GP IIb/IIIa administration
ended to reduce index PCI-related ischemic events in poor
esponders (7.1% vs. 13.2%, p  0.08) but not in full
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Values are n (%).
FR  full responder; PR  poor responder; ST  stent thrombosis; TIMI  Thrombolysis In Myocardial
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October 26, 2010:1447–55 Outcomes and Post-PCI Aspirin and Clopidogrel Responsivenessesponders (4.7% vs. 5%, p  0.6). Based on the pre-
pecified periprocedural MI definition consisting of 3
LN troponin I/T elevation, overall, there were 114
13.8%) periprocedural MIs, which were again more fre-
uent among poor responders (28.4% vs. 6.4%, p  0.01).
t multivariable analysis, both aspirin and clopidogrel poor
esponsiveness along with multivessel PCI were identified as
ndependent predictors (Table 3). GP IIb/IIIa inhibition
ignificantly reduced PCI-related MIs among poor re-
ponders (21.2% vs. 34.7%, p  0.02) but failed to do so
mong full responders (6.3% vs. 6.5%, p  0.8) (Fig. 3). At
OC analysis, %PI values 20 (AUC: 0.76, 95% CI: 0.69
o 0.82; sensitivity 78% and specificity 68%) and PRU values
210 (AUC: 0.8, 95% CI: 0.73 to 0.88; sensitivity 75% and
pecificity 78%) were identified as optimal cut offs. At
ensitivity analysis focused on patients who did not receive
P IIb/IIIa inhibitors, the cut offs remained largely
nchanged.
TO 360 DAYS. Overall, 18 (2.2%) deaths, 32 (3.9%) MIs,
nd 2 (0.2%) strokes were observed after day 3 up to 1 year.
he composite end point was 9.3% in poor responders
ersus 4.4% in responders (p  0.007) (Table 2). This
nding is principally due to worse outcome of clopidogrel
oor responders as compared with full responders (Fig. 4).
t multivariable analysis, clopidogrel poor response and
eriprocedural MI were both independent predictors of
dverse events (Table 3). Periprocedural MI still remained
ndependently associated with a worse 1-year outcome
ased on both CK-MB 3 ULN definition (HR: 1.25,
5% CI: 1.14 to 1.37) and troponin 3 ULN definition
HR: 1.2, 95% CI: 1.1 to 1.28). As for the periprocedural
vents, GP IIb/IIIa inhibitor administration did not influ-
nce long-term outcome in full responders (3.6% vs. 3.7%,
 0.9 at log-rank) (Fig. 5, blue lines). Contrarily, we
ended to observe fewer adverse events in poor responders
eceiving GP IIb/IIIa as compared with patients not receiv-
ng it, without reaching statistical significance (9.5% vs.
1.9%, p  0.3 log-rank) (Fig. 5, red lines).
Screened for Aspirin Screened for Clopidogrel
41)
PR
(n  124) p Value
FR
(n  289)
PR
(n  179) p Value
) 5 (4) 0.3 5 (1.7) 4 (2.2) 0.4
) 0 (0) 0.5 0 (0) 2 (1.1) 0.2
) 14 (11.3) 0.4 13 (4.5) 29 (16.2) 0.001
) 16 (13) 0.4 17 (5.9) 31 (17.3) 0.001
) 10 (8.1) 0.4 8 (2.8) 20 (11.1) 0.004
) 11 (8.3) 0.3 11 (3.8) 17 (9.5) 0.02
) 3 (2.5) 0.1 2 (0.6) 3 (1.7) 0.3
) 4 (3.2) 0.1 3 (1) 5 (2.8) 0.1
) 0 (0) 0.6 2 (0.6) 1 (0.5) 0.8
) 3 (2.5) 0.5 9 (3.1) 4 (2.2) 0.4Figure 2 ARU and PRU
(A) Aspirin reactivity units (ARU) and (B) P2Y12 reactivity units (PRU) values
distribution in our study population. CI  confidence interval.ecurrence of Adverse Events in Study PopulationTable 2 Recurrence of Adverse Events in Study Population
Adverse Events
Overall Study Population
FR
(n  548)
PR
(n  278) p Value
FR
(n  4
Death 10 (1.8) 8 (2.9) 0.4 7 (1.3
Stroke 0 (0) 2 (0.2) 0.2 1 (0.2
Myocardial infarction 40 (7.3) 40 (14.3) 0.001 37 (8.4
Composite primary end point 47 (8.6) 44 (15.8) 0.002 44 (10
0 to 3 days 27 (4.9) 28 (10.1) 0.008 26 (5.9
3 to 365 days 24 (4.4) 26 (9.3) 0.007 20 (4.5
Definite ST 5 (0.9) 5 (1.8) 0.2 4 (0.9
Definite/probable ST 7 (1.3) 8 (2.9) 0.1 5 (1.1
TIMI major bleeding 4 (0.7) 1 (0.3) 0.5 2 (0.4
TIMI minor bleeding 20 (3.6) 7 (2.5) 0.4 14 (3.1Infarction.
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n this prospective study of a large number of low-risk
atients undergoing PCI with dual antiplatelet therapy
reatment, we found that clopidogrel poor response, as
easured by a point-of-care assay, is an independent
redictor of 1-year adverse events. Poor response to
lopidogrel similarly impacted on both periprocedural
nd nonprocedural major cardiovascular events with an
dentified cut-off value in the range of 210 for PRU and
0% for %PI for both. Contrarily, aspirin poor response
s associated with higher risk of periprocedural MI, but it
ailed to remain associated with worse outcomes at
ong-term follow-up.
Current data complement and extend the findings from
redictors of Primary Composite End PointTable 3 Predictors of Primary Composite End Point
HR 95% CI p Value
1-year primary end point
(18 deaths, 80 MIs, 2 strokes; 12.1%)
Univariate analysis
Prior MI 1.13 1.06–1.20 0.01
Clopidogrel poor response 1.20 1.10–1.30 0.01
Multivessel PCI 1.09 1.03–1.16 0.01
Multivariable analysis
Clopidogrel poor response 1.30 1.07–1.56 0.01
Primary end point 0 to 3 days
(55 MIs; 6.6% using 3 ULN
of CK-MB definition)
Univariate analysis
Clopidogrel poor response 1.19 1.09–1.28 0.01
Multivessel PCI 1.11 1.04–1.18 0.01
Multivariable analysis
Clopidogrel poor response 1.15 1.05–1.35 0.01
Multivessel PCI 1.10 1.01–1.32 0.04
(114 MIs; 13.8% using 3 ULN of
troponin I/T definition)
Univariate analysis
Aspirin poor response 1.27 1.17–1.37 0.01
Clopidogrel poor response 1.39 1.28–1.50 0.01
Multivessel PCI 1.32 1.24–1.40 0.01
Multivariable analysis
Aspirin poor response 1.18 1.01–1.35 0.04
Clopidogrel poor response 1.30 1.07–1.56 0.01
Multivessel PCI 1.26 1.05–1.51 0.01
Primary end point 3 to 365 days
(18 deaths, 32 MIs, 2 strokes; 5.1%)
Univariate analysis
Clopidogrel poor response 1.15 1.05–1.29 0.01
Prior MI 1.10 1.03–1.18 0.02
Prior CABG 1.09 1.02–1.16 0.01
Diabetes mellitus 1.08 1.02–1.15 0.02
Peri-PCI MI (CK-MB 3) 1.24 1.17–1.32 0.01
Multivariable analysis
Clopidogrel poor response 1.12 1.06–1.25 0.03
Peri-PCI MI (CK-MB 3) 1.25 1.14–1.37 0.01
I  confidence interval; CK-MB  creatine kinase-myocardial band; HR  hazard ratio; ULN 
pper limit of normal; other abbreviations as in Table 1.revious studies. As compared to previously, we enrolled a veryow-risk patient population (patients with stable coronary
rtery disease and negative cardiac markers) (4), we evaluated
oth aspirin and clopidogrel response (4,5,10,11), we used a
apid point-of-care (VerifyNow System) assay (5,6), and the
ccurrence of both periprocedural MI and long-term clinical
utcomes was investigated (4–6,10–12).
Despite a remarkable body of literature focusing on
aspirin resistance,” its definition, diagnosis, prevalence,
auses, and clinical consequences are still uncertain (13).
irect comparison of different laboratory methods to detect
spirin resistance showed relatively weak or even no corre-
ation, indicating that they are sensitive to different param-
ters. In addition, studies that measured serum thrombox-
ne B2 levels in aspirin-treated patients reported a
revalence of “aspirin resistance” that ranged between 1%
nd 1.7% (14). Therefore, aspirin resistance, when tested
ppropriately with cyclooxygenase (COX)-1 specific assays,
ppears to be extremely rare, and in most instances, due to
nderdosing or noncompliance issues.
Our current analysis provides 2 interesting findings:
) aspirin poor response, as evaluated by VerifyNow, pre-
icts periprocedural MI but not 1-year clinical outcome;
Figure 3 Rate of Periprocedural MI
(A) Periprocedural myocardial infarction (MI) in patients stratified according to
aspirin response and glycoprotein IIb/IIIa inhibitors (GPI) administration. (B)
Periprocedural MI in patients stratified according to clopidogrel response and
GPI administration. Blue bars  full responders; red bars  poor responders.
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October 26, 2010:1447–55 Outcomes and Post-PCI Aspirin and Clopidogrel Responsivenessnd 2) in patients who underwent screening for both aspirin
nd clopidogrel, poor response to aspirin only was uncom-
on (1.5%), similar to the previously reported incidence of
spirin resistance based on serum thromboxane B2 levels
14), and much lower than the prevalence observed among
atients who underwent screening for aspirin only (27%).
herefore, it is plausible to speculate that the VerifyNow
ystem may not be a suitable assay to test aspirin COX-1
ediated response. In particular, aspirin poor response, as
etected with the VerifyNow system, may simply identify
igh pre- and on-treatment platelet reactivity more than a
eal failure of aspirin to “hit the target,” namely, to inhibit
OX-1 activity. Thus, the previously reported capability of
spirin resistance, as detected with this assay, to predict
orse cardiovascular outcomes (11) may reflect clopidogrel
oor responsiveness or high residual on-treatment platelet
eactivity. Thus, altogether our data, in keeping with emerg-
ng evidence based on more sophisticated and more COX-1
Figure 4 Cumulative Incidence of 1-Year Primary
End Point for Aspirin and Clopidogrel
Cumulative incidence of 1-year primary end point, excluding periprocedural
events. (A) Full responders to aspirin (blue line) versus poor responders to
aspirin (red line). (B) Full responders to clopidogrel (blue line) versus poor
responders to clopidogrel (red line).pecific platelet assays (15–19), questions the value of a purespirin resistance phenomenon, and provides a possible
xplanation for the contrasting evidence available in the
iterature (10,11,15–19).
Clopidogrel is a prodrug that must be metabolized in the
iver by several cytochrome P (CYP) proteins, including
YP3A and CYP2C19, to become active and to inhibit
denosine diphosphate-induced platelet aggregation (2).
here is growing evidence that the response to clopidogrel
ay be influenced by pharmacokinetic variables such as
ntestinal absorption and metabolic activation in the liver,
oth of which are affected by genetic polymorphisms (2).
ur data confirm that clopidogrel poor responder patients
ere at increased risk during PCI of periprocedural MI and
hen, during the follow-up, of death, stroke, and MI.
nterestingly, our ROC analysis identified cut offs of %PI
nd PRU values slightly lower as compared with those
reviously reported (4,12,20). Nevertheless, our cut offs,
hile slightly lower, still coincide with the upper quartile
alue of our study population, as it was in all previous
tudies (12). Probably, this finding is due to the low-risk
rofile of our patients (stable coronary disease and negative
ardiac markers vs. moderate- to high-risk acute coronary
yndromes) (21). In keeping with this hypothesis, it has
een well documented that platelet reactivity, as well as drug
esponsiveness, is influenced by clinical presentation, it
eing higher in patients with MI as compared with patients
ho have stable angina or silent ischemia (21,22). A
otential important consequence of this observation is that
he best cut-off value for platelet hyper-reactivity to predict
orse cardiovascular outcomes during treatment may be
isease specific.
Figure 5 Cumulative Incidence of 1-Year Primary End Point for
Aspirin/Clopidogrel Response and GP Inhibitors Use
Cumulative incidence of 1-year primary end point, excluding periprocedural
events. Blue lines  full responders; red lines  poor responder. Solid lines
 glycoprotein (GP) IIb/IIIa inhibitor administration during percutaneous coro-
nary intervention (PCI). Dotted lines  no GP IIb/IIIa administration during PCI.
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Outcomes and Post-PCI Aspirin and Clopidogrel Responsiveness October 26, 2010:1447–55In the 3T/2R main study, we found that GP IIb/IIIa
nhibitor administration significantly reduces periprocedural
I in poor responder patients (8). In this analysis, we
learly showed that the protective effect of GP IIb/IIIa
nhibitor is restricted to poor responders, whereas no benefit
as observed in full responders to aspirin and/or clopi-
ogrel, confirming that a tailored intensification of anti-
latelet activity is the best strategy to further improve the
linical outcome of low-risk patients undergoing PCI.
reviously, periprocedural MI has been associated with
orse clinical outcome (23,24). In our study, periprocedural
I is an independent predictor of composite end point,
nderlining the need for carefully tailoring intensity of
ntithrombotic treatment at the time of coronary interven-
ion. We believe that GP IIb/IIIa inhibitor therapy still
emains a very attractive option to reduce the periprocedural
schemic burden of poor responsiveness (8), especially in
linical settings where delaying the procedure to allow more
omplete platelet inhibition by clopidogrel is questionable
nd not cost effective (25). While prasugrel or ticagrelor
ay also be attractive strategies to overcome clopidogrel
oor responsiveness, there are currently no data to support
heir use in stable patients undergoing elective PCI. Finally,
P IIb/IIIa therapy is an optimal strategy to reduce
eriprocedural events and to improve short-term outcome.
lthough this may have a positive effect, different strategies
or maintenance therapy (e.g., higher doses or switch to
ther drugs) should be tested to optimize the long-term
utcome of poor responder patients.
tudy limitations. This is a complementary study of the
T/2R trial, so several limitations are present. First, there
s no formal sample size calculation; thus, our data should
e regarded as hypothesis-generating. Second, the use of
P IIb/IIIa inhibitors was randomized only for poor
esponder patients; therefore, the data of full responder
atients should be considered exploratory. Third, for
atients receiving 600 mg clopidogrel, 2 h may be not
ufficient to obtain a steady-state effect. However, our
ime between loading dose and PCI was longer (4.1 
.1 h). Finally, not all the study population was screened
or both tests. Nevertheless, all analyses comparing
creened patients and patients not screened for aspirin or
lopidogrel excluded any influence on short- and long-
erm clinical outcome results.
onclusions
oor response to clopidogrel is an independent predictor of
eriprocedural MI and a worsening of a 1-year clinical
utcome in low-risk patients with stable coronary artery
isease who are undergoing PCI, even after excluding
eriprocedural events from the analysis. Contrarily, poor
esponse to aspirin failed to consistently and independently
redict a worse outcome. In keeping with recent data (19),
his result suggests that aspirin resistance should remain
nder scrutiny. Finally, contrary to what was previously
1eported for poor responder patients (8), GP IIb/IIIa
nhibitors failed to provide a benefit for aspirin and/or
lopidogrel full responders.
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